IL315617A - Preparations with improved bioavailability of drugs and their uses - Google Patents

Preparations with improved bioavailability of drugs and their uses

Info

Publication number
IL315617A
IL315617A IL315617A IL31561724A IL315617A IL 315617 A IL315617 A IL 315617A IL 315617 A IL315617 A IL 315617A IL 31561724 A IL31561724 A IL 31561724A IL 315617 A IL315617 A IL 315617A
Authority
IL
Israel
Prior art keywords
therapeutics
compositions
improved bioavailability
bioavailability
improved
Prior art date
Application number
IL315617A
Other languages
English (en)
Hebrew (he)
Inventor
Daniel Gooding
John Brew
Robin M Bannister
Original Assignee
Trx Biosciences Ltd
Daniel Gooding
John Brew
Robin M Bannister
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed by Trx Biosciences Ltd, Daniel Gooding, John Brew, Robin M Bannister filed Critical Trx Biosciences Ltd
Publication of IL315617A publication Critical patent/IL315617A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL315617A 2022-03-14 2023-03-14 Preparations with improved bioavailability of drugs and their uses IL315617A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Publications (1)

Publication Number Publication Date
IL315617A true IL315617A (en) 2024-11-01

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315617A IL315617A (en) 2022-03-14 2023-03-14 Preparations with improved bioavailability of drugs and their uses

Country Status (7)

Country Link
EP (1) EP4493151A2 (de)
JP (1) JP2025509680A (de)
AU (1) AU2023233811A1 (de)
CA (1) CA3245873A1 (de)
IL (1) IL315617A (de)
WO (1) WO2023174948A2 (de)
ZA (1) ZA202407659B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025072929A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of California Methods and compositions of treating age-related conditions
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
EP2220073B1 (de) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinonderivate als parp-inhibitoren
ME02640B (de) * 2008-10-07 2017-06-20 Kudos Pharm Ltd Pharmazeutische formulierung 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
CA2865040C (en) * 2012-02-21 2020-07-14 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
EA201690608A1 (ru) * 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US11629118B2 (en) * 2017-03-03 2023-04-18 Inspirna, Inc. Formulations with improved stability
AU2019363244B2 (en) * 2018-10-15 2024-10-03 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Also Published As

Publication number Publication date
WO2023174948A3 (en) 2023-10-26
CA3245873A1 (en) 2023-09-21
AU2023233811A1 (en) 2024-09-19
EP4493151A2 (de) 2025-01-22
JP2025509680A (ja) 2025-04-11
ZA202407659B (en) 2026-01-28
WO2023174948A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
IL315617A (en) Preparations with improved bioavailability of drugs and their uses
IL306029A (en) Preparations with improved bioavailability of medical treatments
IL310530A (en) Stabilized compositions of radionuclides and their uses
PL4090332T3 (pl) Kompozycje podstawionych pirazolopirymidyn i ich zastosowania
IL304159A (en) A preparation containing bl-8040
IL318328A (en) Compositions comprising multi-agonist peptides and methods for making and using them
IL325330A (en) Solid forms of posiphen d-tartrate
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL287137A (en) Preparations and methods for administration of healing substances
IL315862A (en) Angiotensinogen modulators and methods of using them
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
GB202012765D0 (en) Compositions and methods of production thereof
GB202411091D0 (en) Compositions and uses
GB202215065D0 (en) Compositions and uses thereof
GB202209335D0 (en) Compositions and uses thereof
GB202406865D0 (en) Novel compounds and therapeutics uses thereof
GB202311665D0 (en) Modification of composition
GB201919385D0 (en) Compositions and methods of manufacture
IL319457A (en) Staurosporine analog compounds and uses thereof
IL316654A (en) Preparation and uses of 7-azaindenoisoquinolines
GB202405768D0 (en) Compositions and uses of oligo-chromopeptides and methods of making
GB202312354D0 (en) Novel compounds, compositions and therapeutics uses thereof
GB202215064D0 (en) Compositions and uses thereof
GB202213726D0 (en) Compositions and uses thereof
GB202210107D0 (en) Compositions and uses thereof